1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Liver Cancer - Pipeline Review, 2015

Liver Cancer - Pipeline Review, 2015

  • October 2015
  • -
  • Global Data
  • -
  • 76 pages

Liver Cancer - Pipeline Review, 2015

Summary

GlobalData's Medical Devices sector report, “Liver Cancer - Pipeline Review, 2015" provides an overview of Liver Cancer diagnostic tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Cancer diagnostic tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Liver Cancer diagnostic tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Liver Cancer diagnostic tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Liver Cancer diagnostic tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table Of Contents

Liver Cancer - Pipeline Review, 2015
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Introduction 7
2.1 Liver Cancer Overview 7
3 Products under Development 8
3.1 Liver Cancer - Pipeline Products by Stage of Development 8
3.2 Liver Cancer - Pipeline Products by Territory 9
3.3 Liver Cancer - Pipeline Products by Regulatory Path 10
3.4 Liver Cancer - Pipeline Products by Estimated Approval Date 11
4 Liver Cancer - Pipeline Products under Development by Companies 12
4.1 Liver Cancer Companies - Pipeline Products by Stage of Development 12
4.2 Liver Cancer - Pipeline Products by Stage of Development 14
5 Liver Cancer Companies and Product Overview 16
5.1 Abbott Diagnostics Company Overview 16
5.1.1 Abbott Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 16
5.2 Almac Diagnostics Limited Company Overview 23
5.2.1 Almac Diagnostics Limited Pipeline Products and Ongoing Clinical Trials Overview 23
5.3 AXO Science S.A.S. Company Overview 24
5.3.1 AXO Science S.A.S. Pipeline Products and Ongoing Clinical Trials Overview 24
5.4 BioMark Technologies Inc. Company Overview 28
5.4.1 BioMark Technologies Inc. Pipeline Products and Ongoing Clinical Trials Overview 28
5.5 China Sky One Medical, Inc. Company Overview 29
5.5.1 China Sky One Medical, Inc. Pipeline Products and Ongoing Clinical Trials Overview 29
5.6 Digna Biotech, S.L. Company Overview 30
5.6.1 Digna Biotech, S.L. Pipeline Products and Ongoing Clinical Trials Overview 30
5.7 Drexel University Company Overview 32
5.7.1 Drexel University Pipeline Products and Ongoing Clinical Trials Overview 32
5.8 German Cancer Research Center Company Overview 35
5.8.1 German Cancer Research Center Pipeline Products and Ongoing Clinical Trials Overview 35
5.9 Glycotest, Inc. Company Overview 36
5.9.1 Glycotest, Inc. Pipeline Products and Ongoing Clinical Trials Overview 36
5.10 Imperial College London Company Overview 37
5.10.1 Imperial College London Pipeline Products and Ongoing Clinical Trials Overview 37
5.11 IntegraGen SA Company Overview 38
5.11.1 IntegraGen SA Pipeline Products and Ongoing Clinical Trials Overview 38
5.12 Matrix-Bio, Inc. Company Overview 40
5.12.1 Matrix-Bio, Inc. Pipeline Products and Ongoing Clinical Trials Overview 40
5.13 NanoString Technologies, Inc. Company Overview 42
5.13.1 NanoString Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 42
5.14 National Cancer Institute Company Overview 44
5.14.1 National Cancer Institute Pipeline Products and Ongoing Clinical Trials Overview 44
5.15 Orion Genomics LLC Company Overview 47
5.15.1 Orion Genomics LLC Pipeline Products and Ongoing Clinical Trials Overview 47
5.16 PleX Diagnostics Company Overview 49
5.16.1 PleX Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 49
5.17 ProMIS Neurosciences Inc. Company Overview 50
5.17.1 ProMIS Neurosciences Inc. Pipeline Products and Ongoing Clinical Trials Overview 50
5.18 Proplex Technologies, Llc Company Overview 52
5.18.1 Proplex Technologies, Llc Pipeline Products and Ongoing Clinical Trials Overview 52
5.19 Proteome Sciences Plc Company Overview 54
5.19.1 Proteome Sciences Plc Pipeline Products and Ongoing Clinical Trials Overview 54
5.20 Roche Diagnostics International Ltd. Company Overview 56
5.20.1 Roche Diagnostics International Ltd. Pipeline Products and Ongoing Clinical Trials Overview 56
5.21 TrovaGene, Inc. Company Overview 58
5.21.1 TrovaGene, Inc. Pipeline Products and Ongoing Clinical Trials Overview 58
5.22 University of Chicago Company Overview 60
5.22.1 University of Chicago Pipeline Products and Ongoing Clinical Trials Overview 60
5.23 University of Rochester Company Overview 62
5.23.1 University of Rochester Pipeline Products and Ongoing Clinical Trials Overview 62
5.24 Viomics Inc. Company Overview 63
5.24.1 Viomics Inc. Pipeline Products and Ongoing Clinical Trials Overview 63
5.25 XEPTAGEN SpA Company Overview 64
5.25.1 XEPTAGEN SpA Pipeline Products and Ongoing Clinical Trials Overview 64
5.26 Xiamen Zeesan Biotech Co.,Ltd Company Overview 71
5.26.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products and Ongoing Clinical Trials Overview 71
6 Liver Cancer- Recent Developments 72
7 Appendix 73
7.1 Methodology 73
7.2 About GlobalData 75
7.3 Contact Us 76
7.4 Disclaimer 76

1.1 List of Tables
Table 1: Liver Cancer - Pipeline Products by Stage of Development 8
Table 2: Liver Cancer - Pipeline Products by Territory 9
Table 3: Liver Cancer - Pipeline Products by Regulatory Path 10
Table 4: Liver Cancer - Pipeline Products by Estimated Approval Date 11
Table 5: Liver Cancer Companies - Pipeline Products by Stage of Development 12
Table 6: Liver Cancer - Pipeline Products by Stage of Development 14
Table 7: Abbott Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 16
Table 8: ARCHITECT c16000 System - PIVKA Assay - Product Status 17
Table 9: ARCHITECT c16000 System - PIVKA Assay - Product Description 17
Table 10: ARCHITECT c4000 System - PIVKA Assay - Product Status 18
Table 11: ARCHITECT c4000 System - PIVKA Assay - Product Description 18
Table 12: ARCHITECT c8000 System - PIVKA Assay - Product Status 19
Table 13: ARCHITECT c8000 System - PIVKA Assay - Product Description 19
Table 14: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Status 20
Table 15: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Description 20
Table 16: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Status 21
Table 17: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Description 21
Table 18: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Status 22
Table 19: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Description 22
Table 20: Almac Diagnostics Limited Pipeline Products and Ongoing Clinical Trials Overview 23
Table 21: Prognostic Test - NSCLC - Product Status 23
Table 22: Prognostic Test - NSCLC - Product Description 23
Table 23: AXO Science S.A.S. Pipeline Products and Ongoing Clinical Trials Overview 24
Table 24: Multiplexed Detection - Des-Carboxy Prothrombin - Product Status 25
Table 25: Multiplexed Detection - Des-Carboxy Prothrombin - Product Description 25
Table 26: Multiplexed Detection - Matrix metalloproteinase 1 - Product Status 26
Table 27: Multiplexed Detection - Matrix metalloproteinase 1 - Product Description 26
Table 28: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Status 27
Table 29: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Description 27
Table 30: BioMark Technologies Inc. Pipeline Products and Ongoing Clinical Trials Overview 28
Table 31: Biomarker Assay - Hepatocellular Cancer - Product Status 28
Table 32: Biomarker Assay - Hepatocellular Cancer - Product Description 28
Table 33: China Sky One Medical, Inc. Pipeline Products and Ongoing Clinical Trials Overview 29
Table 34: Diagnostic Kit - Liver Cancer - Product Status 29
Table 35: Diagnostic Kit - Liver Cancer - Product Description 29
Table 36: Digna Biotech, S.L. Pipeline Products and Ongoing Clinical Trials Overview 30
Table 37: HCC Molecular Marker Assay - Product Status 30
Table 38: HCC Molecular Marker Assay - Product Description 30
Table 39: Oxidated APO-A1 Assay - Product Status 31
Table 40: Oxidated APO-A1 Assay - Product Description 31
Table 41: Drexel University Pipeline Products and Ongoing Clinical Trials Overview 32
Table 42: Diagnostic Test - Liver Cancer - Product Status 33
Table 43: Diagnostic Test - Liver Cancer - Product Description 33
Table 44: Glycan-Based Biomarker Assay - Liver Cancer - Product Status 34
Table 45: Glycan-Based Biomarker Assay - Liver Cancer - Product Description 34
Table 46: German Cancer Research Center Pipeline Products and Ongoing Clinical Trials Overview 35
Table 47: RAGE Based Diagnostic Assay - Liver Cancer - Product Status 35
Table 48: RAGE Based Diagnostic Assay - Liver Cancer - Product Description 35
Table 49: Glycotest, Inc. Pipeline Products and Ongoing Clinical Trials Overview 36
Table 50: Diagnostic Test - Liver Cancer - Product Status 36
Table 51: Diagnostic Test - Liver Cancer - Product Description 36
Table 52: Imperial College London Pipeline Products and Ongoing Clinical Trials Overview 37
Table 53: Diagnostic Assay - HCC - Product Status 37
Table 54: Diagnostic Assay - HCC - Product Description 37
Table 55: IntegraGen SA Pipeline Products and Ongoing Clinical Trials Overview 38
Table 56: Diagnostic Test - Hepatocellular Carcinoma - Product Status 39
Table 57: Diagnostic Test - Hepatocellular Carcinoma - Product Description 39
Table 58: Matrix-Bio, Inc. Pipeline Products and Ongoing Clinical Trials Overview 40
Table 59: VeraMarker Liver Cancer Screening - Product Status 40
Table 60: VeraMarker Liver Cancer Screening - Product Description 40
Table 61: VeraMarker Liver Cancer Test - Product Status 41
Table 62: VeraMarker Liver Cancer Test - Product Description 41
Table 63: NanoString Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 42
Table 64: In Vitro Diagnostic Assay - HCC Gene Signature - Product Status 43
Table 65: In Vitro Diagnostic Assay - HCC Gene Signature - Product Description 43
Table 66: National Cancer Institute Pipeline Products and Ongoing Clinical Trials Overview 44
Table 67: HCC Gene Signature Diagnostic Test - Product Status 45
Table 68: HCC Gene Signature Diagnostic Test - Product Description 45
Table 69: HCC Gene Signature Prognostic Test - Product Status 46
Table 70: HCC Gene Signature Prognostic Test - Product Description 46
Table 71: Orion Genomics LLC Pipeline Products and Ongoing Clinical Trials Overview 47
Table 72: Diagnostic Assay - Liver Cancer - Product Status 48
Table 73: Diagnostic Assay - Liver Cancer - Product Description 48
Table 74: PleX Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 49
Table 75: HCCpleX - Product Status 49
Table 76: HCCpleX - Product Description 49
Table 77: ProMIS Neurosciences Inc. Pipeline Products and Ongoing Clinical Trials Overview 50
Table 78: Screening Test - Liver Cancer - Product Status 51
Table 79: Screening Test - Liver Cancer - Product Description 51
Table 80: Proplex Technologies, Llc Pipeline Products and Ongoing Clinical Trials Overview 52
Table 81: Biomarker Diagnostic Test - Liver Cancer - Product Status 53
Table 82: Biomarker Diagnostic Test - Liver Cancer - Product Description 53
Table 83: Proteome Sciences Plc Pipeline Products and Ongoing Clinical Trials Overview 54
Table 84: Biomarker Assay - Liver Cancer - Product Status 55
Table 85: Biomarker Assay - Liver Cancer - Product Description 55
Table 86: Roche Diagnostics International Ltd. Pipeline Products and Ongoing Clinical Trials Overview 56
Table 87: Glypican-3 MAb Companion Diagnostic Test - Product Status 57
Table 88: Glypican-3 MAb Companion Diagnostic Test - Product Description 57
Table 89: TrovaGene, Inc. Pipeline Products and Ongoing Clinical Trials Overview 58
Table 90: Diagnostic Test - Liver Cancer - Product Status 59
Table 91: Diagnostic Test - Liver Cancer - Product Description 59
Table 92: University of Chicago Pipeline Products and Ongoing Clinical Trials Overview 60
Table 93: Paxillin Prognostic Biomarker - Liver Cancer - Product Status 61
Table 94: Paxillin Prognostic Biomarker - Liver Cancer - Product Description 61
Table 95: University of Rochester Pipeline Products and Ongoing Clinical Trials Overview 62
Table 96: Biomarker Test - HCC - Product Status 62
Table 97: Biomarker Test - HCC - Product Description 62
Table 98: Viomics Inc. Pipeline Products and Ongoing Clinical Trials Overview 63
Table 99: Diagnostic Assay - Liver Cancer - Product Status 63
Table 100: Diagnostic Assay - Liver Cancer - Product Description 63
Table 101: XEPTAGEN SpA Pipeline Products and Ongoing Clinical Trials Overview 64
Table 102: compleXima HCC Biochip - Liver Cancer - Product Status 65
Table 103: compleXima HCC Biochip - Liver Cancer - Product Description 65
Table 104: DCP-IgM Kit - Liver Cancer - Product Status 66
Table 105: DCP-IgM Kit - Liver Cancer - Product Description 66
Table 106: GPC3-IgM Kit - Liver Cancer - Product Status 67
Table 107: GPC3-IgM Kit - Liver Cancer - Product Description 67
Table 108: Osteopontin-IgM Kit - Liver Cancer - Product Status 68
Table 109: Osteopontin-IgM Kit - Liver Cancer - Product Description 68
Table 110: Survivin-IgM Kit - Liver Cancer - Product Status 69
Table 111: Survivin-IgM Kit - Liver Cancer - Product Description 69
Table 112: VEGF-IgM Kit - Liver Cancer - Product Status 70
Table 113: VEGF-IgM Kit - Liver Cancer - Product Description 70
Table 114: Xiamen Zeesan Biotech Co.,Ltd Pipeline Products and Ongoing Clinical Trials Overview 71
Table 115: Theranostic - Liver Cancer Metastasis - Product Status 71
Table 116: Theranostic - Liver Cancer Metastasis - Product Description 71
Table 117: Glossary 74

1.2 List of Figures
Figure 1: Liver Cancer - Pipeline Products by Stage of Development 8
Figure 2: Liver Cancer - Pipeline Products by Territory 9
Figure 3: Liver Cancer - Pipeline Products by Regulatory Path 10
Figure 4: Liver Cancer - Pipeline Products by Estimated Approval Date 11

Companies Mentioned
Abbott Diagnostics
Almac Diagnostics Limited
AXO Science S.A.S.
BioMark Technologies Inc.
China Sky One Medical, Inc.
Digna Biotech, S.L.
Drexel University
German Cancer Research Center
Glycotest, Inc.
Imperial College London
IntegraGen SA
Matrix-Bio, Inc

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.